Pharmacy

Greenphire, the industry leading provider of clinical payment communication technology solutions, has recently announced the launch of its Clinical GPS technology, a unique site payment solution that streamlines and automates the clinical payment process for sponsors of all sizes.  Green hire’s Clinical GPS solution utilizes a proprietary validation engine that is capable of analyzing data and triggering payments to a recipient  based on customizable terms negotiated within a contract. By centralizing all payment activity through a technology driven system, Clinical GPS is capable of providing detailed reporting at the site, investigator and vendor level for a single study or across a number of studies. Samuel Whitaker, CEO at Greenphire comments: "Currently we are the only company to offer a centralized reporting and auditing tool for clinical trial payments.

 Bio Rad Laboratories, Inc has recently launched industry leading usability with the new colour touch screens for the C1000 Touch thermal cycler, CFX96 Touch and CFX384 Touch real-time PCR detection turnaround time, flexibility, and adjustable throughput. The CFX96 Touch and CFX384 Touch systems combine the optical technology of the CFX optical reaction modules with the precise thermal control  systems, part of the Bio-Rad 1000-series product line. Researchers can use the enhanced user interface to easily edit, run and save protocols. The design allows users of the CFX96 Touch and the CFX384 Touch to view qPCR amplification traces in real time without an attached computer. The C1000 Touch thermal cycler is ideal for large high-throughput labs, core facilities, and GLP labs that value fast and usability of the C1000 Touch™ chassis. These systems are ideal for labs that value high performance, ease of use and high throughput. Researchers who would like more...

Thermo Fisher Scientific Inc recently announced a breakthrough workflow to overcome key analytical and informatics challenges in metabolomics. The workflow integrates new application software- Thermo Scientific SIEVE 2.0 differential expression analysis and Mass Frontier 7.0 structural elucidation software with powerful new Thermo Scientific High Resolution Accurate mass (HRAM) instruments: the Q Executive™ high performance bench top quadrupole-Ortemp™ LC-MS/MS and the Orbitrap Elite™ hybrid mass spectrometer. The revolutionary new products accelerate even the most complex metabolomics studies Thermo Fisher Scientific in North America. "The new capability in SIEVE™ 2.0 software eliminates the most significant bottlenecks in current metabolomics data-processing, enabling scientists to find the most promising putative biomarkers quickly." SIEVE™ software is an automated solution for label-free, semi-quantitative differential expression analysis of proteins, peptides and metabolites. Using this software to pre-filter the high-quality accurate mass data generated by Thermo Scientific mass revolutionary new products accelerate even me most complex metabolomics studies. more...

A large part of the task of supply chain mangers and logistics companies is to shoulder the responsibility of ensuring patient safety along with doctors. If the drug is not supplied at the right time and in right condition then health of the patients will be affected. The Supply Chain Management (SCM) companies need smooth functioning and certain roadblocks need to be overcome to achieve patient safety and satisfaction. Titash Roy Choudhury The   Indian   pharmaceutical market is expected to reach $20 billion by 2015, growing at a compound annual growth rate (CAGR) of 11.7 per cent during 2005-2015 and establish its presence among the world's leading 10 markets, according to a report by Ernst & Young. "It is one of the fastest growing sectors in India currently," states Prakash Rochlani, Vice President - Business Development, SSEA, DHL Supply Chain. But the most interesting part of this growth is that it more...

Medical writing primarily involves writing on topics for the medical fraternity as well the common man. As the healthcare market is growing, demand for healthcare information is also increasing. Outsourcing is on a growing curve, since India has a pool of qualified and experienced professionals. A look at the fast-growing discipline. Escalating cost of drug development, exhausting pipeline of effective molecules, expiry of patents, fierce competition from generics and the economic recession have put a lot of pressure on the global pharma industry for cost containment and maintaining profitability.  The recent German legislation to control healthcare costs that proposes linking the prices of drugs with their efficacy may further add to worry of pharmaceutical companies and force them to strictly control the R&D costs. To manage these challenges many companies are trying to reduce their overhead costs by focusing on their core R&D strengths and entering into strategic partnerships with more...

...says Philip Nyren, Product Group Manager, Cole-Parmer. Discussing the use, applications and advantages of peristaltic pumps, Nyren explains the solutions that help customers do their jobs.   Meghna Mukherjee & Arshia Khan   Kindly state the use and functionality of peristaltic pumps in the pharmaceutical industry and explain how this technology is cost-effective? Peristaltic pumps are suitable for the dispensing, metering and general transfer of fluids. They are used in the pharmaceutical sector for media transfer, dosing, dispensing, filling, acid-base control and other applications. Peristaltic pumps are well suited to pumping a variety of fluids. The fluid is contained in a flexible tube that is fitted tightly within the pump. A rotating set of rollers alternately compress and relax the tubing. As the tube relaxes, the resulting vacuum draws fluid forward and this pocket of fluid is then captured as the next roller moves into place. This compression cycle essentially more...

Rising incidences of cancer warrants equal high treatment costs. Continuous research coupled with advances in molecular biology, genetics, genomics, proteomics have led to the identification of novel molecular targets for cancer therapy and prevention. One such major breakthrough is the cancer vaccine. Presently, there are high unmet needs that these vaccines can cater to. An analysis.   At present, the global cancer vaccines market is occupied by cervical and prostate cancer    vaccines.    The vaccines available for cervical cancer are all prophylactic; the brands are Gardasil and Cervarix. The only therapeutic     vaccine     available in the market is Provenge from Dendreon Corporation. The global cervical cancer vaccine market in 2009 was worth $1.41 billion. GlobalData has estimated that the global cervical cancer market will grow at a Compounded Annual Growth Rate (CAGR) of 5 per cent to reach $2.10 billion in 2017. The cost of three complete dose courses of cervical cancer more...

Sun Pharmaceutical Industries Ltd, recently announced that US Food ' and Drug Administration (USFDA) has granted its US subsidiary an approval to market a generic version of sumatriptan succinate injection. This is the first Abbreviated New Drug Application (ANDA) approval for a sumatriptan auto injector. The pharmaceutical company has got the permission to market - this injection in strength of 6 mg (base)/0.5 m. Annual sale for sumatriptan succinate injections in the US is approximately $190 million. Sumatriptan succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes. This generic injection packaged in a single-dose syringe with auto injector is equivalent to Imitrex9 STAT dose System, 6 mg (base) 0.5 mL of GlaxoSmithKline.

India's biopharma sector may see a surge in R&D spending to about $25 billion in the next “.5 -years, according to a Boston Consulting Group (BCG) report that said favourable policies need to be implemented to attract investment and enhance innovation in the field. The paper was presented at the US-India Bio-Pharma summit organised by the USA-India Chamber of Commerce (USAIC) on June 24, 2011.  The   total   amount currently being spent   on   innovative discovery    programmes and development in the biopharma sector in India is about $2 billion. This amount can grow to $25 billion by 2025 if concerted efforts are made by various stakeholders like the government, academia and industry on developing R&D and innovation in the biopharma field. The investment is expected to come from multinationals, Indian industry and funding organizations ploughing money into discovery and innovation. "The Indian government needs to implement favourable policies that enhance innovation and more...

Jubilant Biosys, a unit of Jubilant Life Sciences, recently       announced that it has received an undisclosed amount as a milestone payment from AstraZeneca for its research on pain management in the neuroscience therapeutic area.  "The collaboration, which was initiated two years ago in neuroscience therapeutic area, has now expanded to cardiovascular and metabolic diseases and focuses on the delivery of a steady stream of pre-clinical outcomes to AstraZeneca by Jubilant," stated a press release by Jubilant Life Sciences. Commenting  on  the development, Sri mosut) CEO & President, Jubilant Global Drug Discovery and Development, said, "We are pleased that we have delivered outcomes and  early success  to the portfolio efforts at AstraZeneca.   This   is the result of excellent collaboration     between scientists at Jubilant and AstraZeneca." The alliance between Jubilant and London headquartered drug firm AstraZeneca in the neuroscience  therapeutic area began two year ago. AstraZeneca own: the compound; developed under the more...